^
    4ms
    Case report of non-gene editing CD7 CAR T cell therapy in CD7+ Sézary syndrome: preclinical validation and first-in-human use. (PubMed, Front Immunol)
    The CD7 CAR construct possesses a "safety switch" (RTX) to enable rapid depletion of the CAR T treatment with administration of rituximab. However, this study supports the importance of thorough tumor characterization and the potential use of CD7-RTX CAR T cells to treat a variety of malignancies expressing CD7. Future clinical trials are required to characterize the safety and efficacy of CD7-RTX CAR T cells.
    P1 data • Preclinical • Journal
    |
    CD7 (CD7 Molecule)
    |
    Rituxan (rituximab) • CD7 CAR-T Cell
    over3years
    CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma (clinicaltrials.gov)
    P1, N=24, Recruiting, iCell Gene Therapeutics | Trial completion date: Oct 2023 --> Jun 2024 | Initiation date: Nov 2021 --> Jul 2022 | Trial primary completion date: Oct 2023 --> Jun 2024
    Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    CD7 CAR-T Cell
    almost4years
    CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma (clinicaltrials.gov)
    P1, N=24, Recruiting, iCell Gene Therapeutics
    New P1 trial • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    CD7 CAR-T Cell